Company presentations are an integral programming element at the BIO CEO & Investor Conference that allow companies to discuss their pipeline, R&D activities, and future goals to this exclusive audience. Companies and organizations present at the BIO CEO & Investor Conference to get in front of an exclusive audience of public and private equity investors, plus other biotech executives.
The conference features 13-minute presentations by over 150 biotech companies poised to join the growth “watch list”, as well as a number of nonprofit and venture philanthropy organizations. The typical audience for all presentations features public and private equity investors, research analysts, investment bankers and industry executives.
Presenters benefit from a critical mass of decision-makers that you want to meet under one roof for two focused days, to tell your company’s story and attract the partners you need to succeed in developing innovations to help patients.
Please note: There are a limited number of reduced rate Discovery and Emerging Innovator rate company presentations available which will be assigned on a first come, first serve basis. After they are sold out, companies are still be able to present at the standard Biotech/Pharma rate.
Approved for a Company Presentation? Click here for more information.
Approximately 140 companies have already been hand-selected to showcase their pipelines, licensing and investment goals, including Newron Pharmaceuticals, XyloCor Therapeutics, Anima Biotech, and Greenwich LifeSciences, plus our Buzz of BIO winners: Breakthrough Genomics, AZTherapies, and Brainstorm Cell Therapeutics.
Companies and organizations present at the BIO CEO & Investor Conference to get in front of an exclusive audience of public and private equity investors, plus other biotech executives. Presenters also receive exclusive benefits not available to general attendees, including pre-conference marketing, and designation in the BIO One-on-One Partnering™.
Presenters are public and established private companies that have raised >$25M, as well as earlier stage discovery companies that have raised <$9M, and emerging innovator companies (between $9M and $25M raised). Presenters must have a biotech R&D focus and a pipeline involving therapeutics, diagnostics, genomics, or platform technologies for human health. Patient advocacy groups may also apply to present.